Methods of treating neurological conditions with...

Details Methods of treating neurological conditions with... Methods of treating neurological conditions with...

2007-10-31

2011-12-06

Bunner, Bridget E (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S007700, C514S007900, C530S350000

Reexamination Certificate

active

08071543

ABSTRACT:
The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

REFERENCES:
patent: 4810643 (1989-03-01), Souza
patent: 5599690 (1997-02-01), Fenton et al.
patent: 2002/0151488 (2002-10-01), Lauffenburger et al.
patent: 2002/0198150 (2002-12-01), Chajut
patent: 2004/0120925 (2004-06-01), Toda et al.
patent: 2004/0141946 (2004-07-01), Schaebitz et al.
patent: 2005/0003453 (2005-01-01), Sarkar et al.
patent: 2005/0142102 (2005-06-01), Schaebitz et al.
patent: 2007/0243160 (2007-10-01), Toda et al.
patent: 2009/0087481 (2009-04-01), Schaebitz et al.
patent: 2010/0284926 (2010-11-01), Schneider et al.
patent: 2213906 (1998-03-01), None
patent: 100 33 219 (2002-01-01), None
patent: 231819 (1987-08-01), None
patent: 0 327 545 (1987-09-01), None
patent: 272703 (1988-06-01), None
patent: 0661057 (1995-05-01), None
patent: 1 374 898 (2002-01-01), None
patent: 1 327 449 (2003-07-01), None
patent: 3-503418 (1991-08-01), None
patent: 1992000357539 (1991-09-01), None
patent: 4-198134 (1992-07-01), None
patent: 05246885 (1993-09-01), None
patent: 2002-530068 (2002-09-01), None
patent: 2002-281962 (2002-10-01), None
patent: WO 87/01132 (1987-02-01), None
patent: WO 89/09060 (1989-10-01), None
patent: WO 97/14307 (1997-04-01), None
patent: WO 99/17798 (1999-04-01), None
patent: WO 99/61445 (1999-12-01), None
patent: WO 99/61446 (1999-12-01), None
patent: WO 00/04926 (2000-02-01), None
patent: WO 00/44785 (2000-08-01), None
patent: WO 02/22163 (2002-03-01), None
patent: WO 02/072144 (2002-09-01), None
patent: 02/099081 (2002-12-01), None
patent: WO 02/099081 (2002-12-01), None
patent: 03/061685 (2003-07-01), None
patent: WO 2004/011632 (2004-02-01), None
Bederson et al., Stroke. 1986; 17: 472-6.
Tan et al., J Interv Cardiol. Aug. 2001; 14: 465-74.
Matchett et al., Brain Research, 2007; 1136: 200-207.
Whalen et al., Crit Care Med. 1999, 27: 1014-1018—HTML version only available; downloaded Feb. 9, 2010; 9 pages total.
Lawrence et al., Journal of Vascular Surgery, 1998, 27: 329-337.
Sevimli et al., Experimental Neurology, 2009; 217: 328-335.
Strecker et al., Experimental Neurology; 2010, 222: 108-113.
U.S. Appl. No. 10/331,755, filed Dec. 31, 2002, Schaebitz, et al.
U.S. Appl. No. 11/846,699, filed Aug. 29, 2007, Schaebitz, et al.
U.S. Appl. No. 11/930,758, filed Oct. 31, 2007, Schaebitz, et al.
U.S. Appl. No. 11/931,128, filed Oct. 31, 2007, Schaebitz, et al.
U.S. Appl. No. 11/931,326, filed Oct. 31, 2007, Schaebitz, et al.
U.S. Appl. No. 11/931,618, filed Oct. 31, 2007, Schaebitz, et al.
U.S. Appl. No. 11/932,383, filed Oct. 31, 2007, Schaebitz, et al.
Tarkowski, et al, “Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia”, Acta Neurol Scand, 2001:103: 166-174.
Tarkowski, et al., “Intrathecal release of pro- and anti-inflammatory cytokines during stroke”, Clin Exp Immunol, 1997;110:492-499.
Tarkowski, et al., “Intrathecal Expression of Proteins Regulating Apoptisis in Acute Stroke”, Apoptosis During Stroke, Feb. 1999.
Heard, et al., “Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage”, Crit Care Med, 1998, vol. 26, No. 4, pp. 748-754.
Patterson, The emerging neuropoietic cytokine family: first CDF/LIF, CNTF and IL-6; next ONC, MGF, GCSF?, Current Biology, Ltd. vol. 2, No. 1, (1992).
Konishi, et al., “Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo”, Brain Research, 609, (1993), pp. 29-35.
Zavala, et al., “G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokine-Based Immune Deviation”, Article by the American Association of Immunologists (2002), pp. 2011-2019.
Suzumara, et al., “Selective induction of interleukin-6 in mouse microglia by granulocyte-macrophage colony-stimulating factor”, Brain Research, 713 (1996), pp. 192-198.
Lee, et al., “GM-CSF Promotes Proliferation of Human Fetal and Adult Microglia in Primary Cultures”, GLIA 12:309-318 (1994).
Guillemin, et al., “Granulocyte Macrophage Colony Stimulating Factor Stimulates In Vitro Proliferation of Astrocytes Derived From Simian Mature Brains”, GLIA, 16:71-80 (1996).
Dame, et al., “The Distribution of Granulocyte-Macrophage Colony-Stimulating Factor and its Receptor in the Developing Human Fetus”, Pediatric Research, vol. 46, No. 4, (1999), pp. 358-366.
Dame, et al., “The effect of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) on granulocyte macrophage-colony stimulating factor (GM-CSF) production by neuronal precursor cells”, Eur. Cytokine Netw, vol. 13, No. 1, Mar. 2002, pp. 128-133.
Baldwin, et al., “Identification and Characterization of a High-Affinity Granulocyte-Macrophage Colony-Stimulating Factor Receptor on Primary Rat Oligodendrocytes”, Blood, vol. 82, No. 11, Dec. 1, 1993, pp. 3279-3282.
Konishi, et al., “Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo”, Brain Research, 609 (1993) 29-35.
Schaebitz W. R. et al: “Recombinant Granulocyte-Colony Stimulating Factor (RG-CSF) is Neuroprotective Following Focal Transient Cerebral Ischemia and Excitotoxity” Society for Neuroscience Abstracts,Society for Neuroscience, US, vol. 27, No. Part 2, Nov. 10, 2001, p. 2027, AN76411, XP008009334, ISSN: 0190-5295 the whole document.
Konishi Y, et al.: “Trophic Effect of Erythropoietin and Other Hematopoietic Factors on Central Cholinergic Neurons in Vitro an in Vivo.”, Brain Research, Apr. 23, 1993, vol. 609, Nos. 1-2, pp. 29-35, XP001183386 ISSN: 0006-8993, Abstract, Introduction, p. 29, Discussion pp. 32-34.
Hierholzer, et al., “Activation of Stat Proteins Following Ischemia Reperfusion Injury Demonstrates a Distinct IL-6 and G-CSF Mediated Profile.”, Transplantation Proceedings, Sep. 1998, vol. 30, No. 6, p. 2647, XP001182894, ISSN: 0041-1345 the whole document.
Tian Shin-Shay, et al.: “Multiple Signaling Pathways Induced by Granulocyte Colony-Stimulating Factor Involving Activation of JAKs, STAT5, and/or STAT3 Are Required for Regulation of Three Distinct Classes of Immediate Early Genes” Blood, vol. 88, No. 12, 1996, pp. 4435-4444 XP001183387 ISSN: 0006-4971 the whole document.
Ward Alister, et al., “Tyrosine-Dependent and—Independent Mechanisms of STAT3 Activation by the Human Granulocyte Colony-Stimulating Factor (G-CSF) Receptor Are Differentially Utilized Depending on G-CSF Concentration”, Blood, vol. 93, No. 1, Jan. 1, 1999 pp. 113-124 XP001183113, ISSN: 0006-4971 the whole document.
Schaebitz, et al. “Neuroprotective Effect of Granulocyte Colony-Stimulating Factor After Focal Cerebral Ischemia.”, Stroke, vol. 34, No. 3, Mar. 2003, pp. 745-751, XP002294803, ISSN: 0039-2399 the whole document.
Iverson et al., Proc Nat. Acad. Sci. 1996; 93: 2785-2789.
Tavernier et al., Proc. Nat. Acad. Sci. 1995; 92:5194-5198.
International Preliminary Examination Report as received in corresponding PCT/IB 03/06446 filed Dec. 31, 2003.
Wells, 1990, Biochemistry 29:8509-8517; Ngo et al., 1994. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Bork, 2000, Genome Research 10:398-400.
Skolnick, et al., 2000. Trends in Biotech. 18(1):34-39.
Doerks, et al., 1998, Trends in Genetics 14:248-250.
Smith et al., 1997, Nature Biotechnology 15:1222-1223.
Brenner, 1999, Trends in Genetics 15:132-133.
Bork, et al., 1996, Trends in Genetics 12:425-427.
Lee, et al., NeuroImmunoModulation, 2004; 11:279-292.
Emerich, et al., Clin Pharmacokinet. 2001; 40: 105-23.
Klein, et al. BMC Neurosci. 2007; 8-61.
Kreyden, et al. Hautarzt. 2001. 52:327-330.
Farese, et al. Stern Cells. 2001; 19:522-53

Affiliated with

Also associated with

Rating

Methods of treating neurological conditions with... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating neurological conditions with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating neurological conditions with... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4266289